JAMA Dermatology Publishes Results from Verrica’s Two Pivotal Phase III CAMP (Cantharidin Application in Molluscum Patients) Trials
September 23, 2020 16:05 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 22nd Annual Global Investment Conference
September 09, 2020 07:30 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Pharmaceuticals Licenses LTX-315, A First-in-Class Oncolytic Peptide Based Immunotherapy, from Lytix Biopharma AS, for the Treatment of Dermatologic Oncology Indications
August 11, 2020 07:00 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Pharmaceuticals Reports Second Quarter 2020 Financial Results
August 05, 2020 07:01 ET
|
Verrica Pharmaceuticals Inc.
- Company intends to request a Type A meeting with FDA during the third quarter of 2020 to discuss next steps for resubmission of an NDA for VP-102 following Complete Response Letter - - Key...
Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102 in Japan
August 05, 2020 07:00 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases...
Verrica Pharmaceuticals Announces Dr. Lawrence Eichenfield Joins Board of Directors
July 23, 2020 07:31 ET
|
Verrica Pharmaceuticals Inc.
– Leading pediatric dermatologist brings significant expertise in the treatment of skin diseases to help inform development of the Company’s product candidates – WEST CHESTER, Pa., July 23, 2020 ...
Verrica Pharmaceuticals Announces Clinical and Drug Development Leadership Changes
July 23, 2020 07:30 ET
|
Verrica Pharmaceuticals Inc.
– Dr. Gary Goldenberg appointed Chief Medical Officer; Dr. Brad Catalone assumes the role of Head of Drug Development – – New leadership strengthens expertise in Clinical, Chemistry, Manufacturing,...
Verrica Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
July 14, 2020 07:00 ET
|
Verrica Pharmaceuticals Inc.
– Complete Response Letter Requests Additional Chemistry, Manufacturing, and Controls (CMC) and Human Factors Information – – No Clinical Safety or Efficacy Issues Identified – – Conference Call and...
Verrica Pharmaceuticals Provides Regulatory Update on VP-102
June 29, 2020 16:05 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., June 29, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases...
Verrica Pharmaceuticals Announces Positive Results from Two New Pooled Analyses of the Phase 3 CAMP Trials of VP-102 in Molluscum Contagiosum
June 12, 2020 10:00 ET
|
Verrica Pharmaceuticals Inc.
- Pre-specified exploratory analysis showed VP-102 brought about a statistically significant percentage of patients with complete molluscum lesion clearance across all lesion count quartiles compared...